TGFβ contributes to mesangial cell hypertrophy and matrix protein increase in various kidney diseases including diabetic nephropathy. Deptor is an mTOR-interacting protein and suppresses mTORC1 and mTORC2 activities. We have recently shown that TGFβ-induced inhibition of deptor increases the mTOR activity. The mechanism by which TGFβ regulates deptor expression is not known. Here we identify deptor as a target of the microRNA181a. We show that in mesangial cells, TGFβ increases the expression of miR-181a to downregulate deptor. Decrease in deptor augments mTORC2 activity, resulting in phosphorylation/activation of Akt kinase. Akt promotes inactivating phosphorylation of PRAS40 and tuberin, leading to stimulation of mTORC1. miR-181a-mimic increased mTORC1 and C2 activities, while anti-miR-181a inhibited them. mTORC1 controls protein synthesis via phosphorylation of translation initiation and elongation suppressors 4EBP-1 and eEF2 kinase. TGFβ-stimulated miR-181a increased the phosphorylation of 4EBP-1 and eEF2 kinase, resulting in their inactivation. miR-181a-dependent inactivation of eEF2 kinase caused dephosphorylation of eEF2. Consequently, miR-181a-mimic increased protein synthesis and hypertrophy of mesangial cells similar to TGFβ. Anti-miR-181a blocked these events in a deptor-dependent manner. Finally, TGFβ-miR-181a-driven deptor downregulation increased the expression of fibronectin. Our results identify a novel mechanism involving miR-181a-driven deptor downregulation, which contributes to mesangial cell pathologies in renal complications.
Introduction
Pathologic features of chronic kidney disease include infiltration of inflammatory cells, leading to capillary rarefaction, podocyte depletion, tubular atrophy and fibrosis [1] . Recruited inflammatory cells secrete pro-fibrogenic cytokines including transforming growth factorβ (TGFβ), which directly and indirectly contribute to the phenotypic alterations of the resident kidney cells including glomerular mesangial cells [2] . Mesangial cells constitute one third of the glomerular cell population and respond to TGFβ by undergoing hypertrophy and increasing synthesis of matrix proteins, leading to mesangial expansion [3] . The homodimeric TGFβ binds to the constitutively active TGFβ receptor II on the mesangial cell membrane to recruit TGFβ receptor I, which phosphorylates the receptor-specific Smad 2 and Smad 3 at their Ctermini. Phosphorylated Smads then bind to the co-Smad, Smad 4 and translocate to the nucleus to regulate transcription of select genes [4] . TGFβ also activates Smad-independent non-canonical signaling that includes, PI 3 kinase, Erk1/2, JNK, p38 MAPK and mTOR [5] .
microRNAs are noncoding RNAs that act as physiological and pathological regulators for post-transcriptional gene expression [6, 7] . They bind predominantly to the 3′untranslated region of mRNAs with imperfect complementarity to suppress their translation. In human cells 1, 657 miRNAs have been validated for RNA interference [8] . miRNAs are synthesized in the nucleus as primary transcripts, which undergo cleavage by the ribonuclease III Drosha to form precursor miRNAs. PremiRs are transported by exportin-5 to the cytosol where they are further processed by dicer to form mature miRNAs. Mature miRNAs then interact with the 3′UTR of target mRNA in an RNA-induced silencing complex to repress mRNA translation [7] . Recognition of miRNAs in renal injury came from studies in which renal podocyte-specific deletion of dicer in mouse resulted in proteinuria [9] .
Mechanistic target of rapamycin (mTOR) is coded by a single gene and forms two distinct kinase complexes, mTORC1 and mTORC2, which contain common subunit mLST8 that interacts with the kinase domain [10] . Presence of PRAS40 and raptor in mTORC1 distinguishes it from mTORC2, while the latter uniquely contains rictor and mSin1 [10] . Recently, deptor has been identified as a component of both these kinase complexes [11] . Deptor acts as a negative regulator of mTORC1 and mTORC2. We have recently shown that TGFβ downregulates deptor to increase mTOR activity [12] . However, the mechanism by which deptor is downregulated by TGFβ is not known. Here we show that miR-181a induced by TGFβ targets deptor mRNA 3′UTR to suppress its expression. We demonstrate that miR-181a regulates the TGFβ-stimulated mTORC1 and mTORC2 activities involved in glomerular mesangial cell hypertrophy and fibronectin expression.
Materials and methods
Reagents: Tissue culture materials and TRI reagent for preparing RNA were purchased from Thermo Fisher. Protease inhibitor cocktail and Na 3 VO 4 were purchased from Sigma. Recombinant TGFβ1 was obtained from R & D Systems. Antibodies for phospho-Akt (Ser-473), phospho-Akt (Thr-308), phospho-GSK3β (Ser-9), phospho-PRAS40 (Thr-246), phospho-tuberin (Thr-1462), phospho-S6 kinase (Thr-389), phospho-ribosomal protein s6 (rps6) (Ser-240/244), phospho-4EBP-1 (Thr-37/46), phospho-eEF2 kinase (Ser-366) and phospho-eEF2 (Thr-56), Akt, GSK3β, PRAS40, S6 kinase, rps6, 4EBP-1, eEF2 kinase and eEF2 were purchased from Cell Signaling. Antibodies against tuberin and deptor were purchased from Santa Cruz. FLAG and actin antibodies were from Sigma. pMirTarget Deptor 3′-UTR luciferase (Deptor 3′-UTRLuc) reporter plasmid was purchased from OriGene Technologies. OPTIMEM transfection medium, siRNA against deptor and the primers for detecting mature miR-181a, U6 RNA, miR-181a mimic and antimiR-181a were obtained from Thermo Fisher. FuGENE HD transfection reagent was purchased from Promega.
Cell Culture: Rat glomerular mesangial cells prepared from rat were grown in DMEM with low glucose in the presence of 17% serum as described previously [13] [14] [15] . The cells were grown to confluency before incubation in the serum free DMEM for 18-24 h. The cells were incubated with 2 ng/ml TGFβ for 24 h or as indicated.
RNA isolation and real time PCR: Total RNAs were prepared using the TRI reagent according to the vendor's protocol. cDNAs were prepared and used to detect miR-181a using the real time PCR machine (7500, Applied Biosystems). U6 primers were used to normalize the data as described previously [16, 17] .
Cell lysis and immunoblotting: After the incubation period, RIPA buffer was added to the cells for 30 min at 4°C. Lysed cells were scrapped off the plates and centrifuged at 14,000×g for 30 min at 4°C. The supernatant was collected and protein concentration was determined. Equal amounts of proteins were separated by SDS polyacrylamide gel electrophoresis. The separated proteins were transferred to PVDF membrane. The membrane containing the proteins was immunoblotted with indicated antibodies. HRP-conjugated secondary antibodies were used and the protein bands were visualized using chemiluminiscence on X-ray film [13, 16] .
Protein synthesis and hypertrophy: Protein synthesis was determined using 35 S-Methionine incorporation as described previously [18] . Hypertrophy of mesangial cells were determined as a ratio of total protein content to the cell number as described previously [19, 20] . Transfection: The mesangial cells were plated in complete medium. Next day the medium was changed to OPTIMEM and the cells were transfected with the plasmid vector, miR-181a mimic or anti-miR-181a using FuGENE HD according to the protocol provided by the vendor as previously described [16, 19] . 4-6 h post-transfection, complete medium was added. The transfected cells were serum starved and treated with TGFβ as described above.
Luciferase activity: The mesangial cells were transfected with Deptor 3′-UTR-Luc reporter plasmid alone or along with miR-181a mimic. Transfected cells were incubated with TGFβ as indicated. The luciferase activity was determined in the cell lysates using a luciferase assay kit as described previously [13, 19] .
Statistics: GraphPad Prism 6 Pro was used. Analysis of variance followed by Tukey's multiple comparison test was used to analyze the data. A p value of less than 0.05 vs was considered significant [15] .
Results

Identification of miR-181a to regulate deptor level
We have shown previously that TGFβ decreases deptor [12] and confirmed it in the present study in rat glomerular mesangial cells ( Supplementary Fig. S1 ). To determine the mechanism of deptor downregulation, we considered the involvement of miRNAs. TargetScan and miRanda analyses of the 3′UTR of deptor mRNA revealed the presence of the recognition element for miR-181a in the human and mouse deptor (Fig. 1A) . We also identified a conserved miR-181a binding site in the rat deptor mRNA 3′UTR (Fig. 1A) . The predicted minimum free energy (ΔG) for binding of miR-181a seed sequence and deptor 3′-UTR for human, mouse and rat is less than −6 kcal/mol ( Supplementary Fig. S2 ). These data support the critical energy requirement for optimal repression of target protein expression [21] . TGFβ significantly increased the expression of miR-181a in a time-dependent manner (Fig. 1B) . To evaluate if miR-181a targets the deptor 3′-UTR, we transfected a reporter plasmid which contains the deptor 3′-UTR fused to the luciferase cDNA (Deptor 3′UTR-Luc) into mesangial cells. Incubation of these cells with TGFβ significantly inhibited the luciferase activity, similar to its effect on deptor expression ( Fig. 1C and  D) . Furthermore, cotransfection of miR-181a mimic with the Deptor 3′-UTR-Luc markedly inhibited the luciferase activity, suggesting the responsiveness of the deptor 3′UTR to this miRNA (Fig. 1E) . Indeed, expression of miR-181a mimic significantly inhibited the levels of deptor similar to TFGβ (Fig. 1F) . These results indicate that miR-181a inhibits deptor expression.
miR-181a controls TGFβ-stimulated mTORC2 activity
Deptor was identified as an inhibitory component of mTOR complexes [11] . To determine whether deptor controls mTORC2 activity, we determined the phosphorylation of its substrate Akt at Ser-473 [22] . We used a plasmid vector expressing FLAG-tagged deptor. Expression of deptor inhibited the TGFβ-induced phosphorylation of Akt at Ser-473 ( Fig. 2A) . Similarly, phosphorylation of Akt at Thr-308 was also inhibited by deptor ( Fig. 2A) . Phosphorylation of Akt at Ser-473 and Thr-308 induces its full kinase activity [23] . This was confirmed by finding that TGFβ increased the phosphorylation of an Akt substrate GSK3β and expression of deptor inhibited it (Fig. 2B) . Similarly, deptor suppressed the phosphorylation of two other Akt substrates, PRAS40 and tuberin, which regulate the activation of mTORC1 (Fig. 2C and D) . We have shown above that TGFβ increases miR-181a to inhibit deptor expression in mesangial cells. Therefore, we examined the effect of miR-181a mimic on mTORC2 activity. Similar to TGFβ, expression of miR-181a mimic increased the phosphorylation of Akt, resulting in enhanced phosphorylation of GSK3β, PRAS40 and tuberin ( Fig. 2E-H) . Furthermore, miR-181a-induced phosphorylation of Akt and its substrates was significantly inhibited by the expression of deptor (Fig. 2I-L) , suggesting that miR-181a-targeted deptor may regulate the mTORC2 to increase Akt activity. To confirm this observation, we used anti-miR181a, which increased the expression of deptor in the presence or absence of TGFβ ( Supplementary Fig S3) . Transfection of anti-miR-181a significantly inhibited the TGFβ-induced phosphorylation of Akt at Ser-473 and Thr-308, which resulted in attenuation of phosphorylation of GSK3β, PRAS40 and tuberin (Fig. 3A-D) . Importantly, the inhibition of these TGFβ-induced phosphorylations by anti-miR-181a was prevented by the expression of siRNA targeting deptor (Fig. 3E-H) . These results conclusively demonstrate that TGFβ-induced miR-181a reduces deptor and enables stimulation of mTORC2 and hence Akt kinase activity.
miR-181a regulates TGFβ-stimulated mTORC1 activity for phosphorylation of mRNA translation initiation factors
Our data above show that miR-181a facilitates mTORC2-dependent phosphorylation of two negative regulators of mTORC1, PRAS40 and tuberin in a deptor-dependent manner. Phosphorylation of these proteins results in their inactivation leading to activation of mTORC1. First, we determined the role of deptor in mTORC1 activity. To measure the mTORC1 activity, we used phosphorylation of its two endogenous substrates, S6 kinase and 4EBP-1, which positively and negatively regulate the initiation phase of mRNA translation, respectively [10] . TGFβ increased the phosphorylation of both these proteins that was inhibited by the expression of deptor ( Fig. 4A and B) . Since phosphorylation of S6 kinase by mTORC1 increases its activity towards the small ribosomal protein s6, we determined its phosphorylation. As shown in Fig. 4C , expression of deptor blocked the TGFβ-stimulated phosphorylation of rps6. Next, we examined the role of miR-181a in mTORC1 activation. Expression of miR-181a mimic increased the phosphorylation of S6 kinase, rps6 and 4EBP-1 similar to those found with TGFβ (Fig. 4D, E and F) . Furthermore, deptor significantly inhibited the miR-181a mimic-induced phosphorylation of these proteins (4 G-4I), suggesting that this microRNA may regulate mTORC1 activity in response to TGFβ via deptor. To confirm this observation, we transfected anti-miR-181a, which led to inhibition of TGFβ-stimulated mTORC1 activity as judged by the phosphorylation of S6 kinase, rps6 and 4EBP-1 (Fig. 5A-C) . siRNA against deptor reversed this inhibition by anti-miR-181a (Fig. 5D-F) .
miR-181a regulates phosphorylation of mRNA translation elongation factors
In addition to the initiation phase, mTORC1 is known to control the elongation phase of mRNA translation via S6 kinase by phosphorylation of eEF2 kinase, which phosphorylates its substrate eEF2 [24] . mTORC1-induced eEF2 kinase phosphorylation inhibits its activity leading to reduced phosphorylation of eEF2, which facilitates peptide elongation [25] . In mesangial cells, TGFβ increased the phosphorylation of eEF2 kinase resulting in dephosphorylation of eEF2. Rapamycin inhibited these reactions ( Supplementary Fig. S4A and B) . We examined the role of miR-181a-targeted deptor in this process. Expression of deptor inhibited the phosphorylation and dephosphorylation of eEF2 kinase and eEF2, respectively ( Fig. 6A and B) . In contrast, miR-181a mimic, respectively, increased and decreased the phosphorylation of eEF2 kinase and eEF2 similar to the TGFβ treatment ( Fig. 6C and D) . However, deptor significantly blocked the miR-181a mimic-induced phosphorylation and dephosphorylation of eEF2 kinase and eEF2, respectively ( Fig. 6E and F) . In conjunction with these results, we found that anti- miR-181a significantly inhibited the TGFβ-stimulated eEF2 kinase phosphorylation, which resulted in the inhibition of the dephosphorylation of eEF2 ( Fig. 6G and H) . Furthermore, these effects of antimiR-181a were prevented by the expression of siRNA against Deptor (Fig. 6I and J) . These results conclusively demonstrate that miR-181a-targeted deptor regulates the elongation phase of the mRNA translation.
miR-181a regulates mesangial cell hypertrophy
We reported previously that TGFβ-induced mesangial cell protein synthesis and hypertrophy are mediated by deptor-dependent mTORC1 regulation [12, 26] . We have shown above that miR-181a-tageted deptor controls key events in the initiation and elongation phases of translation via deptor. Therefore, we determined the role of this microRNA in protein synthesis and hypertrophy. We found that expression of deptor significantly inhibited TGFβ-induced protein synthesis and hypertrophy of mesangial cells (Fig. 7A and B) . In contrast, expression of miR-181a mimic induced protein synthesis and hypertrophy similar to that with TGFβ ( Fig. 7C and D) . Also, expression of deptor inhibited the miR-181a mimic-induced protein synthesis and hypertrophy ( Fig. 7E and F) . To confirm the role of miR-181a, anti-miR-181a significantly blocked TGFβ-induced protein synthesis and hypertrophy ( Fig. 7G and H) . Furthermore, expression of siRNA against deptor reversed the anti-miR-181a-induced inhibition (Fig. 7I and J) . These results demonstrate that miR-181a-targeted deptor reduction regulates TGFβ-induced mesangial cell hypertrophy.
miR-181a controls fibronectin expression
We showed previously that TGFβ increases the expression of the matrix protein fibronectin in mesangial cells [18, 27] . To determine the mechanism, we examined the role of deptor. Expression of deptor significantly inhibited the expression of TGFβ-stimulated fibronectin expression in mesangial cells (Fig. 8A) . On the other hand, miR-181a mimic markedly increased the expression of fibronectin similar to TGFβ while deptor inhibited miR-181a mimic-induced fibronectin expression ( Fig. 8B and C) . Furthermore, anti-miR-181a markedly abrogated the TGFβ-stimulated fibronectin (Fig. 8D) . Importantly, this inhibitory effect of anti-miR-181a was prevented by the expression of siRNAs targeting deptor (Fig. 8E) . Together our results demonstrate that TGFβ-induced miR-181a regulates the mesangial cell fibronectin expression by modulating the expression of deptor.
Discussion
In this report, we show that miR-181a is a mediator of TGFβ in initiating the noncanonical mTOR signaling. We present the first clue that TGFβ-stimulated miR-181a targets deptor to suppress its expression for increasing the mTORC1 and mTORC2 activity. We show that miR-181a-targeted deptor regulates the initiation and elongation factors of mRNA translation that contribute to mesangial cell hypertrophy induced by TGFβ. Finally, we demonstrate the involvement of miR181a and deptor in TGFβ-induced fibronectin expression.
A role of TGFβ in renal fibrosis including hypertrophy and matrix protein expression is established [28] . Along with canonical Smad signaling, TGFβ utilizes the non-canonical PI 3 kinase/Akt/mTOR 
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Experimental Cell Research 364 (2018) [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] pathway for these phenomena [26, 29] . In fact, in fibrotic disorder such as diabetic nephropathy, which is promoted by the action of TGFβ, we and others have shown that rapamycin prevented both mTORC1 and mTORC2 in mice that resulted in reduction in renal hypertrophy and matrix protein expansion [30] [31] [32] [33] . When calcineurin inhibitors were substituted by rapamycin in patients with chronic allograft nephropathy, a significant number of patients developed proteinuria [34] . Also, in renal transplant patients who were treated with rapamycin showed increased proteinuria due to renal damage [35] . In fact, long term treatment of mice with rapamycin showed renal atrophy [31, 36] . Similarly, rapamycin produced loss of renal function in puromycin aminonucleoside-induced nephropathy [37] . Also, loss of mTORC1 as well as mTORC2 in the glomerular cells leads to significant renal injury with albuminuria [36, 38] . Thus complete inhibition of mTOR activity by rapamycin may not be an ideal therapeutic option for TGFβ-mediated renal fibrosis.
Deptor was identified as a partner of both mTORC1 and mTORC2 [11] . In mice deptor gene in chromosome 15 has been linked to obesity [39] . In a murine polygenic model, high expression of deptor in the white adipose tissue correlated with obesity [40] . Furthermore, deptor overexpression in mice promoted white adipose tissue expansion, suggesting its role in fat cell growth. In obese human, level of deptor correlated with the degree of obesity [40] . In certain cancers, deptor acts as an oncogene [41] . However, in many cancers, deptor is downregulated. Transcriptional inhibition and proteasomal degradation of deptor have been reported as mechanisms of downregulation in cancer cells. In conjunction with this notion, we confirmed our previous observation that TGFβ in mesangial cells reduced the expression of deptor [12] . However, as a mechanism, we identified the involvement of TGFβ-induced increase in miR-181a, which targeted the 3′UTR of deptor.
In those cancers where increased expression of deptor induces tumorigenesis, it activates the Akt kinase [42] . Similarly, deptor-mediated Akt activation is necessary for its role in adipogenesis in the obese mouse model and in skeletal muscle during insulin resistance where a metabolic shift from oxidative to glycolysis is observed [43] . In contrast to these results, our data show that overexpression of deptor in mesangial cells significantly blocked the TGFβ-stimulated Akt phosphorylation at the mTORC2 targeted hydrophobic motif site Ser-473. These results are consistent with its role in inhibiting the mTORC2 activity Fig. 7 . miR-181a regulates mesangial cell protein synthesis and hypertrophy via deptor. (A -D) Mesangial cells were transfected with FLAG-tagged deptor (panels A and B) and miR-181a mimic (panels C and D). The cells were incubated with TGFβ (2 ng/ml). (E and F) miR-181a mimic was co-transfected with FLAG-tagged deptor into mesangial cells. (G -J) Mesangial cells were transfected with anti-miR-181a (panels G and H) and anti-miR-181a plus siRNAs against deptor (panels I and J). The cells were incubated with TGFβ. Protein synthesis was determined as 35 S-Methionine incorporation (panels A, C, E, G and I). Hypertrophy was determined as the ratio of protein to cell number (B, D, F, H and J). Bottom parts in panels A, B, E and F show the expression of transfected FLAG-tagged deptor and actin. In panels I and J expression of deptor and actin is shown. Mean ± SE of triplicates is shown. *p < .001 vs control; **p < .001 vs TGFβ or miR-181 mimic (in panels A, B and E -J); @p < .001 vs TGFβ plus anti-miR-181a (in I and J). [11, 22] . Guertin et al. showed that the Thr-308 phosphorylation by PDK-1 was not affected by the ablation of mTORC2 [23, 44] . Interestingly, deptor-mediated inhibition of mTORC2 in mesangial cells also inhibited the PDK-1-dependent Akt Thr-308 phosphorylation. It was reported that the hydrophobic motif site of Akt serves as the docking site for PDK-1, which phosphorylates Akt at Thr-308 [45] . Thus, our results demonstrating lack of Akt Thr-308 phosphorylation by deptor overexpression indicate that deficiency of Akt Ser-473 phosphorylation may block PDK-1 binding and hence inhibits phosphorylation at Thr-308. Negative regulatory role of various microRNAs in renal hypertrophy and fibrosis due to upregulation of TGFβ has been established. Downregulation of miR-29 is associated with renal fibrosis in the TGFβ-dependent mouse models of fibrosis [46] . In fact, overexpression of miR-29 prevented the renal fibrosis in the models of unilateral ureteral obstruction and diabetic nephropathy [47] . This action of miR-29 was due to its ability to target different TGFβ-responsive extracellular matrix-related genes [48] . Similarly, the expression of miR-200a is suppressed in these models of renal fibrosis [49] . On the other hand, multiple microRNAs have been shown to play positive role in kidney hypertrophy and fibrosis [7] . Thus Natarajan and coworkers noted increased expression of miR-192, which resulted in enhanced expression of miR-216 and 217 in the mesangial cells and in the diabetic kidneys [50, 51] . The expression of miR-216 and miR-217, which directly target the tumor suppressor protein PTEN, leads to activation of Akt [51] . We showed previously that TGFβ inhibited the expression of PTEN to induce renal cell hypertrophy and fibronectin expression in mesangial cells [18] . In fact, more recently, we have identified two different microRNAs, miR-21 and miR-214 which are upregulated by TGFβ in diabetic renal fibrosis and they in turn downregulate the expression of PTEN to activate Akt/mTORC1 signaling that contributes to the hypertrophy and matrix protein expression in mesangial cells [15, 27] . In the present study, we show that another microRNA, miR-181a is increased in response to TGFβ in mesangial cells.
miR-181 is a family of four microRNAs (a, b, c and d), which are coded from three different chromosomes with identical seed sequence in the mature microRNAs [52] . miR-181 family is evolutionally conserved among the vertebrates, indicating their important role in physiology. miR-181 was initially found to be highly expressed in the T and B cell lineages although its expression is abundant in lung, brain and bone marrow [53] . miR-181 acts as a tumor suppressor in acute myeloid leukemia [54] . Also, miR-181a regulates antigen sensitivity of T cells during development. [55] . Recent work has revealed that miR181a controls the lymphatic endothelial cell fate [56] . Furthermore, in vascular smooth muscle cells, angiotensin II downregulates miR-181a, which controls their adhesion to collagen by regulating the expression of osteopontin [57] . Thus miR-181a contributes to the pathophysiology of atherosclerosis. Similarly, in cardiac fibroblasts, angiotensin II decreased the expression of miR-181 family suggesting its role in fibrosis [52, 58] . In contrast to these observations, we found that the profibrotic TGFβ increased the expression of miR-181a in glomerular mesangial cells, which contributes to glomerular hypertrophy and glomerulosclerosis. In fact, we for the first time demonstrate a significant role of miR-181a in regulating the TGFβ-induced mesangial cell hypertrophy and fibronectin expression.
In an effort to determine the mechanism of deptor expression, we identified the miR-181a-mediated direct downregulation of deptor, which contributes to the activation of both mTORC2 and mTORC1 in mesangial cells. We and others have reported a role of mTORC1 in the pathologic hypertrophy of the kidney to which TGFβ contributes significantly [18, 27, 31, 32, 59 ]. Under basal state, mTORC1 activity is negatively regulated by two proteins tuberin and PRAS40. The tumor suppressor protein tuberin in complex with hamartin and TBC1D7 inhibits the Rheb-GTP formation, thereby block the mTORC1 activity [10] . Phosphorylation of tuberin inactivates its GAP function towards Rheb-GTP, resulting in activation of mTORC1 [60] . Importantly, phosphorylation of tuberin is significantly increased in the kidneys of patients with fibrotic disorder such as diabetic nephropathy [61] . Similarly, the unphosphorylated mTORC1 component PRAS40 blocks its kinase activity. When phosphorylated by Akt, it dissociates from the mTORC1 complex, leading to its activation [10, 62] . A role of PRAS40 in cardiac hypertrophy has been reported where expression of this protein in cardiomyocyte blocked cardiac hypertrophy [63] . Furthermore, cardiomyocyte-specific overexpression of PRAS40 inhibited mTORC1 activity resulting in decrease in pathological hypertrophy including diabetic cardiomyopathy [63, 64] . We have recently shown that phosphorylation of PRAS40 contributes to the renal cell hypertrophy driven by TGFβ in diabetic nephropathy and in vitro in mesangial cells [20, 27] . Phosphorylation-deficient mutant of PRAS40 inhibited the mTORC1 activity, resulting in inhibition of pathological mesangial cell hypertrophy [20] . Our results here show that miR-181a increases the phosphorylation of tuberin and PRAS40 similar to TGFβ. In fact, miR-181a directly contributes to the phosphorylation of these two mTORC1 inhibitors by targeting deptor.
We and others have established a role of mTORC1 in TGFβ-driven renal hypertrophy and fibrosis [18, [30] [31] [32] 65] . Inhibition of mTORC1 by rapamycin blocked renal hypertrophy and matrix protein expression [30, 32] . We also showed a role for the mTORC1 substrate S6 kinase in the renal cell hypertrophy and matrix protein expression [66] . More recently, using rapamycin in a mice model of increased mTORC1 activity in the kidney, ribosomal protein s6 phosphorylation by S6 kinase was shown to contribute to hypertrophy [67] . However, in this model, rapamycin impaired kidney function leading to premature death of the animals, suggesting a deleterious effect of this macrolide in kidney. In the present study, we demonstrate a significant role of miR-181a in activating the mTORC1 and S6 kinase, where the latter phosphorylates the rps6 similar to TGFβ. Also, our data show direct requirement of miR-181a to suppress deptor expression in TGFβ-stimulated mTORC1 activity. Furthermore, we present the first evidence that inhibition of miR-181a blocked TGFβ-induced mesangial cell hypertrophy and fibronectin expression. Thus our results demonstrate a mechanistic basis for deptor suppression that includes upregulation of miR-181a by TGFβ. Therefore, targeting miR-181a may provide a therapeutic option for renal diseases where TGFβ-driven mesangial cell hypertrophy and matrix protein expression contribute to pathology.
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